TG Therapeutics

is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases. 

Product Pipeline


Ublituximab is a novel, glyco-engineered monoclonal antibody that targets a specific and unique epitope on the B-lymphocyte CD20 antigen, currently in clinical development for hematologic disorders.


TGR-1202 is an orally available PI3K delta inhibitor targeting the delta isoform with nanomolar potency and several fold selectivity over other PI3K isoforms.

For Investors

Stock Quote at: Mar 5, 1:39PM EST

Last: $15.91

Change: $1.06 (7.14%)

Quotes provided by Google - Min 15 minute delay